Improved growth of human skin cells on biomimetic nanofibrous matrices for active wound healing
Project goals
In this Project, the adhesion, growth and phenotypic maturation of human keratinocytes and dermal fibroblasts will be studied in vitro on novel polymeric nanofibrous membranes releasing bioactive amino acids (L-arginine), peptides, such as glycyl-L-histidyl-L-lysine (GHK), macrophage migration inhibitory factor (MIF) and antimicrobial peptides (AMPs), and also coated with cell adhesion-mediating proteins, namely fibrin, collagen and fibronectin. Bilayered constructs of keratinocytes and fibroblasts on the membranes will be created. The membranes will be made of polycaprolactone (PCL) and particularly its copolymer with polylactide (PLA-PCL) of various PLA:PCL ratios in order to regulate the mechanical properties, surface wettability and the degradation rate of the material. Also water-soluble polymers, e.g. polyvinylalcohol, polyethylene oxide and polyvinylpyrrolidon, will be explored. The potential of the meshes releasing bioactive peptides and amino acids to promote and accelerate the active wound healing will be also tested in vivo in experimental skin wound produced in rats.
Keywords
keratinocytesdermal fibroblastsnanofibrous membranesbioactive peptidesamino acidsadhesion proteinswound dressingsactive wound healingskin tissue engineering
Public support
Provider
Czech Science Foundation
Programme
Standard projects
Call for proposals
Standardní projekty 21 (SGA0201700001)
Main participants
Fyziologický ústav AV ČR, v. v. i.
Contest type
VS - Public tender
Contract ID
17-02448S
Alternative language
Project name in Czech
Zvýšený růst lidských kožních buněk na biomimetických nanovlákenných matricích pro aktivní hojení ran
Annotation in Czech
Projekt je zaměřen na studium adheze, růstu a fenotypické maturaci lidských keratinocytů a kožních fibroblastů v kulturách na nově vyvíjených polymerních nanovlákenných membránách uvolňujících bioaktivní aminokyseliny (L-arginin) a peptidy, jako je glycyl-L-histidyl-L-lysin (GHK), faktor inhibující migraci makrofágů (MIF) a antimikrobiální peptidy (AMP). Membrány budou rovněž pokryty proteiny zprostředkující adhesi buněk, jako je fibrin, kolagen a fibronektin, a poslouží k vytvoření dvouvrstevných konstruktů keratinocytů a fibroblastů na protilehlých stranách membrán. Membrány budou připraveny z polykaprolaktonu (PCL), a zejména z jeho kopolymerů s polylaktidem (PLA-PCL) s různým poměrem PLA:PCL pro regulaci mechanických vlastností, smáčivosti a degradability materiálu. Budou vyzkoušeny i polymery rozpustné ve vodě, např. polyvinylalkohol, polyetylén oxid and polyvinylpyrrolidon. Bude rovněž sledována schopnost nanovlákenných membrán uvolňujících bioaktivní peptidy a aminokyseliny podporovat a urychlovat aktivní hojení ran po experimentálně způsobeném poškození kůže u potkana.
Scientific branches
R&D category
ZV - Basic research
CEP classification - main branch
FR - Pharmacology and apothecary chemistry
CEP - secondary branch
EI - Biotechnology and bionics
CEP - another secondary branch
—
20801 - Environmental biotechnology
20802 - Bioremediation, diagnostic biotechnologies (DNA chips and biosensing devices) in environmental management
20803 - Environmental biotechnology related ethics
20901 - Industrial biotechnology
20902 - Bioprocessing technologies (industrial processes relying on biological agents to drive the process) biocatalysis, fermentation
20903 - Bioproducts (products that are manufactured using biological material as feedstock) biomaterials, bioplastics, biofuels, bioderived bulk and fine chemicals, bio-derived novel materials
30104 - Pharmacology and pharmacy
30401 - Health-related biotechnology
30402 - Technologies involving the manipulation of cells, tissues, organs or the whole organism (assisted reproduction)
30403 - Technologies involving identifying the functioning of DNA, proteins and enzymes and how they influence the onset of disease and maintenance of well-being (gene-based diagnostics and therapeutic interventions [pharmacogenomics, gene-based therapeutics])
30404 - Biomaterials (as related to medical implants, devices, sensors)
30405 - Medical biotechnology related ethics
40401 - Agricultural biotechnology and food biotechnology
40402 - GM technology (crops and livestock), livestock cloning, marker assisted selection, diagnostics (DNA chips and biosensing devices for the early/accurate detection of diseases) biomass feedstock production technologies, biopharming
40403 - Agricultural biotechnology related ethics
Solution timeline
Realization period - beginning
Jan 1, 2017
Realization period - end
Dec 31, 2021
Project status
—
Latest support payment
Jun 14, 2019
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP21-GA0-GA-R/13:1
Data delivery date
Feb 22, 2021
Finance
Total approved costs
10,527 thou. CZK
Public financial support
10,131 thou. CZK
Other public sources
396 thou. CZK
Non public and foreign sources
0 thou. CZK
Basic information
Recognised costs
10 527 CZK thou.
Public support
10 131 CZK thou.
96%
Provider
Czech Science Foundation
CEP
FR - Pharmacology and apothecary chemistry
Solution period
01. 01. 2017 - 31. 12. 2021